Guidance On Regulating AI As A Medical Device Not Top 2023 Priority For FDA
Industry Attorney Offers His Perspective On Why It Should Be
The US FDA’s Center for Devices and Radiological Health has posted the guidance documents it plans to focus on in fiscal year 2023, and guidance on regulating AI as a medical device is not first up.
You may also be interested in...
Recently passed legislation that includes higher medical device user fees will allow the US FDA to put more resources into establishing global harmonization standards with international partners.
Nine companies are asked to volunteer for a pilot program that could lead to a new pathway for sponsors of digital health products. Under the plan, the agency would allow firms to market a product with fewer if any pre-market review requirements based on trust developed in the company's software design and testing. If the project works out, FDA digital health leader Bakul Patel tells Medtech Insight, the agency hopes it will attract more non-traditional medical device firms that specialize in software development.
During a recent listening session on modernizing its recall process, the US FDA heard from industry, consumers, and patients — all of whom expressed a common theme: the agency needs to up its game in how it handles recalls.